<DOC>
	<DOCNO>NCT01750814</DOCNO>
	<brief_summary>The primary objective demonstrate immunological non-inferiority GC3102C GC FLU inj . influenza vaccine assess geometric mean titer ( GMTs ) healthy adult</brief_summary>
	<brief_title>To Evaluate Effectiveness ( Immunogenicity ) Safety 'GC3102C ' Administered Intramuscularly Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Healthy adult , 18 &lt; 60 year old Subjets willing provide write informed consent able comply requirement study Subjects history hypersensitivity , especially anaphylactic reaction egg , egg protein , chicken component vaccine gentamicin , gelatin , arginine Subjects history GuillainBarré syndrome Subjects severe chronic disease ( e.g. , cardiovascular disease without controllable hypertension , hemoglobinopathy , respiratory , metabolic , renal disorder ) consider investigator ineligible study Subjects previously treat anticoagulant therapy hemophiliac patient may risk severe hemorrhage intramuscular injection Subjects acute febrile ( least 38.0°C ) episode time 72 hour enrollment Subjects receive vaccination within 7 day enrollment schedule another vaccination ( exclude study vaccine ) study Immunocompromised subject immunodeficiency diseases receive immunosuppressive immunomodulatory therapy , e.g. , azathioprine , cyclosporin , interferon , granulocytecolony stimulate factor , tacrolimus , everolimus , sirolimus Subjects receive highdose corticosteroid 3 month vaccination administer cumulative dose 700 mg corticosteroid study . Inhaled , intranasal , local application corticosteroid permit , regardless dosage , corticosteroid prednisolone maximum dose 15 mg/day allow Subjects administer immunoglobulin bloodderived product 3 month enrollment schedule administration study Subjects receive influenza vaccine within 6 month enrollment A female subject pregnant breastfeeding . Subjects childbearing potential without appropriate contraceptive measure within 30 day enrollment agree use clinically acceptable method birth control study ( e.g. , oral contraceptive , condom , diaphragm intrauterine device , vasectomy male partner ) Subjects participated clinical trial within 30 day administration study vaccine Individuals clinically significant medical psychological condition consider investigator ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>